| 8.61 -0.53 (-5.8%) | 09-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.12  |
1-year : | 11.82 |
| Resists | First : | 9.52 |
Second : | 10.11 |
| Pivot price | 9.39 |
|||
| Supports | First : | 8.55 |
Second : | 7.11 |
| MAs | MA(5) : | 9.16 |
MA(20) : | 9.48 |
| MA(100) : | 9 |
MA(250) : | 12.99 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 5.8 |
D(3) : | 11.1 |
| RSI | RSI(14): 33.4 |
|||
| 52-week | High : | 20.45 | Low : | 7.21 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ADMA ] has closed below the lower bollinger band by 26.0%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ADMA ] is to continue within current trading range. Bollinger Bands are 33.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.19 - 9.28 | 9.28 - 9.33 |
| Low: | 8.37 - 8.49 | 8.49 - 8.55 |
| Close: | 8.48 - 8.66 | 8.66 - 8.77 |
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
Mon, 14 Sep 2026
Why (ADMA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Mon, 14 Sep 2026
Investigation launched into ADMA Biologics for possible revenue inflation via channel-stuffing. - Pluang
Mon, 14 Sep 2026
ADMA Biologics Inc (ADMA) Stock Analysis: A Biotech Gem With 84% Upside Potential - DirectorsTalk Interviews
Fri, 11 Sep 2026
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Thu, 10 Sep 2026
Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Mon, 07 Sep 2026
ADMA Biologics Inc (ADMA) Stock Analysis: A Biotech With 76% Potential Upside - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 224 (M) |
| Shares Float | 220 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 93.2 (%) |
| Shares Short | 22,680 (K) |
| Shares Short P.Month | 24,030 (K) |
| EPS | 0.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.8 |
| Profit Margin | 32.9 % |
| Operating Margin | -123.4 % |
| Return on Assets (ttm) | 21.7 % |
| Return on Equity (ttm) | 41.9 % |
| Qtrly Rev. Growth | 15.8 % |
| Gross Profit (p.s.) | 1.47 |
| Sales Per Share | 2.28 |
| EBITDA (p.s.) | 1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 137 (M) |
| Levered Free Cash Flow | 55 (M) |
| PE Ratio | 12.3 |
| PEG Ratio | 0 |
| Price to Book value | 4.75 |
| Price to Sales | 3.76 |
| Price to Cash Flow | 14.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|